Skip to NavigationSkip to content

peanut allergy

FDA approves first treatment for peanut allergy

The FDA has approved its first treatment for peanut allergy in patients between ages four and 17.

The drug is Aimmune Therapeutics Inc’s Palforzia, or AR101, and patients must take a daily dose to protect themselves from accidental exposure to peanuts. Its reported list price will be $890 a month. Daniel Adelman, the Chief Medical Officer of Aimmune, said: “Not only is PALFORZIA the first approved therapy for peanut allergy, but it is the first approved therapy for any food allergy.”

Aimmune's peanut allergy therapy recommended for approval by FDA committee

The FDA’s Allergenic Products Advisory Committee (APAC) has recommended the use of Aimmune Therapeutics’ AR101, also known by its proposed brand name of Palforzia, in the treatment of peanut allergy among children and teens.

Aimmune's peanut allergy candidate hits main endpoint at Phase 3

US biopharmaceutical firm Aimmune has revealed that its peanut allergy candidate AR101 hit its primary endpoint in the largest trial of its kind, proving that around two-thirds of patients were are able to tolerate at least 600mg of peanut protein - equal to about two average peanut kernels – after taking the drug.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches